COPPER FRACTIONATION IN PROTEINS FROM PLASMA, MUSCLE AND LIVER OF NILE TILAPIA

COPPER FRACTIONATION IN PROTEINS FROM PLASMA, MUSCLE AND LIVER OF NILE TILAPIA. Copper fractionation in plasma, muscle and liver of Nile tilapia was performed after protein separation by 2D-PAGE. SR XRF analysis indicated the presence of copper in three protein spots of plasma, and in two protein spots of muscle and liver, respectively. Copper ions were found to be distributed mostly in proteins that had a molar mass of less than 54 kDa and greater than 13 kat and a pI in the 5.3-9.3 range. The copper concentration bound to these proteins was determined by GFAAS which showed concentrations in the 1.20-4.82 mg g(-1) range.35349349

Attachment of 2,2-bipyridine onto a silica gel for application as a sequestering agent for copper, cadmium and lead ions from an aqueous medium

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)A method was developed to attach 2,2-bipyridine (BP) onto a silica gel surface by a two-step reaction. The first step consisted of a reaction between the matrix and a silylating agent, 3-chloropropyltrimeth-oxysilane. In the second step of the reaction, a ligand molecule was attached onto Si-CPTS, yielding the product Si-BP. The modified material contained 0.431 +/- 0.01 mmol of 2,2-bipyridine per gram of modified silica, as confirmed by FT-IR spectra of the proposed structure. The surface modification was characterized by the BET technique, which revealed a decrease in the surface area from 614 to 450 m(2) g(-1). The series of adsorption isotherms for the metal ions were adjusted to fit a modified Langmuir equation. The maximum number of moles of copper, cadmium and lead ions adsorbed was 0.64, 0.53, and 0.54 mmol g-1, respectively. The surface saturation was calculated as phi fraction and the values obtained, Cu(II) = 1.160, Cd(II) = 1.044 and Pb(II) = 0.997, suggest a type 1:1 metal-ligand complex.1342833Fundação para o Desenvolvimento da UNESP (FUNDUNESP)Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)FUNDUNESP [Proc. 00182/06-DFP]FAPESP [Proc. 06/54946-9

Genetic studies of hypertrophic cardiomyopathy in Singaporeans identify variants in TNNI3 and TNNT2 that are common in Chinese patients

Background - To assess the genetic architecture of hypertrophic cardiomyopathy (HCM) in patients of predominantly Chinese ancestry. Methods - We sequenced HCM disease genes in Singaporean patients (n=224) and Singaporean controls (n=3,634), compared findings with additional populations and Caucasian HCM cohorts (n=6,179) and performed in vitro functional studies. Results - Singaporean HCM patients had significantly fewer confidently interpreted HCM disease variants (Pathogenic (P)/Likely Pathogenic (LP):18%, p<0.0001) but an excess of variants of unknown significance (exVUS: 24%, p<0.0001), as compared to Caucasians (P/LP: 31%, exVUS: 7%). Two missense variants in thin filament encoding genes were commonly seen in Singaporean HCM (TNNI3:p.R79C, disease allele frequency (AF)=0.018; TNNT2:p.R286H, disease AF=0.022) and are enriched in Singaporean HCM when compared with Asian controls (TNNI3:p.R79C, Singaporean controls AF=0.0055, p=0.0057, gnomAD-East Asian (gnomAD-EA) AF=0.0062, p=0.0086; TNNT2:p.R286H, Singaporean controls AF=0.0017, p<0.0001, gnomAD-EA AF=0.0009, p<0.0001). Both these variants have conflicting annotations in ClinVar and are of low penetrance (TNNI3:p.R79C, 0.7%; TNNT2:p.R286H, 2.7%) but are predicted to be deleterious by computational tools. In population controls, TNNI3:p.R79C carriers had significantly thicker left ventricular walls compared to non-carriers while its etiological fraction is limited (0.70, 95% CI: 0.35-0.86) and thus TNNI3:p.R79C is considered a VUS. Mutant TNNT2:p.R286H iPSC-CMs show hypercontractility, increased metabolic requirements and cellular hypertrophy and the etiological fraction (0.93, 95% CI: 0.83-0.97) support the likely pathogenicity of TNNT2:p.R286H. Conclusions - As compared to Caucasians, Chinese HCM patients commonly have low penetrance risk alleles in TNNT2 or TNNI3 but exhibit few clinically actionable HCM variants overall. This highlights the need for greater study of HCM genetics in non-Caucasian populations